Nieuws Wet & Recht Hulpverleners Markt Onderzoek Spierziekten Webwinkel Links Hulpmiddelen Vereniging Mijn VSN Normale lettergrootte Grote lettergrootte Grootste lettergrootte
VSN - Vereniging met veel gezichten
HomeWord lid E-mail Myocafé
   Vereniging Spierziekten Nederland
deze site internet

sitemap: Sitemap lettergrootte: Lettergrootte

Momenteel online:
89 bezoekers
    < Home < Spierziekten < Duchenne spierdystrofie

Duchenne spierdystrofie

Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.
Aartsma-Rus A. e.a.
Human Molecular Genetics 2003 (12) blz. 907

U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping
Brun C. e.a.
Cellular and Molecular Life Sciences 2003 (60) blz. 557

Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer
Cerletti M. e.a.
Gene Therapy 2003 (10) blz. 750

Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle
Dunant P. e.a.
Muscle and Nerve 2003 (27) blz. 624

Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: therapy approach of Duchenne muscular dystrophy
Endesfelder S. e.a.
Journal of Molecular Medicine 2003 (81) blz. 355

Rapid Direct Sequence Analysis of the Dystrophin Gene.
Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, en Weiss RB.
American Journal of Human Genetics 2003 (72) blz. 931-939

107th ENMC International Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7-9 June 2002, Naarden, the Netherlands.
K. Bushby, F. Muntoni, JP Bourke.
Neuromuscular Disorders 2003 (13) blz. 166

Pharmacological strategies for muscular dystrophy.
Khurana TS en Davies KE.
Nature Reviews. Drug Discovery 2003 (2) blz. 379

Beneficial effects of creatine supplementation in dystrophic patients
Louis M e.a.
Muscle and Nerve 2003 (27) blz. 604

Spinal fusion in patients with Duchenne┤s muscular dystrophy and a low forced vital capacity
Marsh A. e.a.
European Spine Journal 2003

Nutritional assessment of patients with neuromuscular diseases.
Pessolano FA e.a.
American Journal of Physical Medicine & Rehabilitation 2003 (82) blz. 183

Antisense-induced multiexon skipping for duchenne muscular dystrophy makes more sense.
Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, Van Ommen GJ, Den Dunnen JT, Van Deutekom JC.
American Journal of Human Genetics 2004 (74) blz. 83

Diagnosis and treatment of enteric neuromuscular diseases
Camilleri M.
Clinical Autonomic Research 2003 (13) blz. 10-15

Measurement of skeletal muscle mass in Duchenne muscular dystrophy : use of 24-h creatinine excretion.
Franciotta D, Zanardi MC, Albertotti L, Orcesi S, Berardinelli A, Pichiecchio A, Uggetti C, Tagliabue A.
Acta Diabetologica 2003 (40) blz. S290

DGGE-based whole-gene mutation scanning of the dystrophin gene in Duchenne and Becker muscular dystrophy patients.
Hofstra RM, Mulder IM, Vossen R, de Koning-Gans PA, Kraak M, Ginjaar IB, van der Hout AH, Bakker E, Buys CH, van Ommen GJ, van Essen AJ, den Dunnen JT.
Human Mutation 2004 (23) blz. 57

The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use.
Jeppesen J, Green A, Steffensen BF, Rahbek J.
Neuromuscular Disorders 2003 (13) blz. 804

Advances in Duchenne muscular dystrophy gene therapy.
Van Deutekom J. en van Ommen G-J
Nature Medicine 2003 (4) blz. 747

Activation of latent myostatin by the BMP1/tolloid family of metalloproteinases
Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ.
Proceedings of the National Academy of Sciences of the United States of America 2003 (100) blz. 15842

Patients with severe muscle wasting are prone to develop hypoglycemia during fasting.
ěrngreen Mc, et al.
Neurology 2003 (61) blz. 997-100

Practical problems and management of seating through the clinical stages of Duchenne┤s muscular dystrophy.
Liu e.a.
Archives of Physical Medicine and Rehabilitation 2003 (84) blz. 818

Cell therapy of a-sarcoglycan null dystrophic mice through intra-arterial delivery of mesangioblasts
M. Sampaolesi e.a.
Science 2003 (301) blz. 487

Bone mineral density and bone metabolism in Duchenne muscular dystrophy.
M.L. Bianchi e.a.
Osteoporosis International 2003 (14) blz. 761

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Q.L.Lu e.a.
Nature Medicine 2003 (9) blz. 1009

Therapeutic effect of camostat mesilate on Duchenne muscular dystrophy in mdx mice.
Sawada e.a.
Biological & Pharmaceutical Bulletin 2003 (26) blz. 1025

Pharmacological strategies for muscular dystrophy
TS Khurana en KE Davies
Nature Reviews. Drug Discovery 2003 (mei) blz. plz. 379

Body composition and energy expenditure in Duchenne muscular dystrophy
Zanardi e.a.
European Journal of Clinical Nutrition 2003 (57) blz. 273

VSN - Lt. gen. van Heutszlaan 6 - 3743 JN Baarn tel: 035-5480480
e-mail: - Bank: ING 1422400

disclaimer - colofon